Header cover image

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

UpdatedAug 09, 2022
DataAggregated Company Financials
Companies6
  • 7D3.8%
  • 3M40.2%
  • 1Y-41.7%
  • YTD-16.7%

Over the last 7 days, the Clinical Research and Equipment industry has remained flat, although notably Genscript Biotech gained 7.9%. As for the longer term, the industry has declined 39% in the last year. Earnings are forecast to grow by 29% annually.

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 09 Aug 2022HK$386.6bHK$22.3bHK$2.0b12.1x189.7x17.4x
Thu, 07 Jul 2022HK$433.0bHK$22.4bHK$2.1b15.1x209.4x19.4x
Sat, 04 Jun 2022HK$299.3bHK$22.5bHK$2.1b13.1x142x13.3x
Mon, 02 May 2022HK$312.2bHK$22.7bHK$2.2b14x145.1x13.8x
Wed, 30 Mar 2022HK$351.9bHK$22.5bHK$2.3b20.3x154.9x15.6x
Fri, 25 Feb 2022HK$337.4bHK$18.8bHK$2.8b20.3x118.9x18x
Sun, 23 Jan 2022HK$461.8bHK$18.7bHK$2.8b31.4x164x24.7x
Tue, 21 Dec 2021HK$455.9bHK$18.6bHK$2.8b32.6x163x24.4x
Thu, 18 Nov 2021HK$581.2bHK$18.6bHK$2.8b35.5x209x31.3x
Sat, 16 Oct 2021HK$560.2bHK$18.5bHK$2.8b52.8x203.1x30.4x
Mon, 13 Sep 2021HK$594.7bHK$18.4bHK$2.7b51.4x216.7x32.3x
Wed, 11 Aug 2021HK$633.3bHK$18.4bHK$2.7b50.8x230.8x34.4x
Sun, 06 Jun 2021HK$611.0bHK$15.7bHK$1.4b58.3x422.9x39x
Wed, 10 Mar 2021HK$456.6bHK$13.1bHK$201.6m71.2x2265.3x34.8x
Tue, 01 Dec 2020HK$359.1bHK$11.4bHK$4.7m63.8x77189.9x31.6x
Fri, 04 Sep 2020HK$330.1bHK$9.7b-HK$169,775,475.5184.1x-1944.1x34.1x
Mon, 08 Jun 2020HK$213.6bHK$9.2bHK$329.6m95.9x647.9x23.1x
Sun, 01 Mar 2020HK$198.4bHK$9.0bHK$860.3m67.3x230.6x22.1x
Wed, 04 Dec 2019HK$167.4bHK$8.2bHK$916.5m58.6x182.6x20.5x
Sat, 07 Sep 2019HK$152.2bHK$7.6bHK$1.0b66x145.1x20x
Price to Earnings Ratio

145.1x


Total Market Cap: HK$152.2bTotal Earnings: HK$1.0bTotal Revenue: HK$7.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Clinical Research and Equipment Industry Price to Earnings3Y Average 6405x202020212022
Current Industry PE
  • Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 193x which is lower than its 3-year average PE of 6kx.
  • The 3-year average PS ratio of 25.8x is higher than the industry's current PS ratio of 17.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 43% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?

HK Market0.21%
Healthcare3.41%
Life Sciences3.81%
Clinical Research and Equipment3.81%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2269 WuXi Biologics (Cayman)HK$74.503.8%
+HK$11.7b
-39.7%PE80.7x
1548 Genscript BiotechHK$28.553.6%
+HK$2.1b
-19.6%PS15x
1873 Viva Biotech HoldingsHK$2.124.4%
+HK$171.8m
-70.8%PE12.1x
1521 Frontage HoldingsHK$2.662.3%
+HK$123.8m
-55.5%PE37.9x
8225 China Health GroupHK$0.324.9%
+HK$14.9m
-19.0%PE9.3x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News